Libidon®
The influence of LIBIDON® on the state of urodynamicsin patients with benign Table 3
prostatic hyperplasia.
Indicator Before After Treatment with After Treatment with
Treatment Conventional Methods Libidon®
Time of urinary retention 4,6±0,3 3,2±0,1* 2,5±0,1*
Number of urinations:
- daytime 8,4±0,5 7,1±0,2* 6,3±0,1*
- nighttime 3,1±0,1 2,8+0,1 2,6+0,1
Abdominal pressure 3,2 2,8 2,4
(measured in points)
The nature of the stream of urine, (measured in points) 3,3 2,6* 2,3*
Average urination rate, (ml/sec) 11,3±1,2 14,2±1,4 17,5±1,6*
Maximum speed of 16,1±2,3 18,2±1,9 20,5±2,1
urination, (ml/sec)
Time to reach the maximum 6,6±0,3 5,3±0,1* 4,5±0,2*
urination rate, (ml/sec
* p <0.05 — significant compared to the values before treatment.
The condition of patients with BPH after treatment with LIBIDON® was characterized by an improve-
ment in subjective and objective indicators of urodynamics. An increase in libido was noted in 37.3%
of patients.
After treatment in patients with BPH stages I and II,uroflograms recorded the restoration of the basic
parameters of urination to normal values. At stage III of the disease, this was prevented by a decrease
in the elasticity of the bladder neck due to sclerotic changes in the tissue of the prostate gland. Still, a
noticeable increase in the urine stream was observed in such patients.
Thus, the results of this study indicate the therapeutic efficacy of LIBIDON® and its use in the complex
treatment of inflammatory diseases of the prostate and dysuric disorders.
LIBIDON® does not cause side effects, complications, or drug dependence and can be used for thera-
peutic and prophylactic purposes, including in combination with any means of symptomatic therapy used
in urological practice (antibacterial agents, antispasmodics, vascular and hormonal drugs, vitamins, etc.)
CONCLUSION
Biologically active food supplement LIBIDON® has a normalizing effect on the functional activity of
prostate cells.
LIBIDON® is well tolerated when taken orally, has no side effects, and can be used as a therapeutic
and prophylactic biologically active food supplement.
LIBIDON® is recommended to patients with chronic prostatitis and prostatic hyperplasia orally with
meals, 1-2 capsules 2 times a day for 30 days.
According to indications, a second course of treatment should be carried out after 3-6 months.
REFERENCES
1. Lyulko A.V., Yunda I.F., Sernyak P.S. and others.- Diseases of the prostate gland. - Kiev: Zdorov’ya,
1984. -- 280 p.
2. Mashkovsky M.D., Medicines: Pharmacotherapy for doctors, manual: 2 parts. – Vilnius: ZAO “Gam-
ta”, 1993.
3. Tkachuk V.N., Gorbachev A.G., Agulyansky L.I. Chronic prostatitis. - L .: Medicine, 1989 .-- 208 p.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.